ACADIA Pharmaceuticals Charts Growth Path After Record Year

ACADIA Pharmaceuticals Inc. ((ACAD)) has held its Q4 earnings call. Read on for the main highlights of the call.

ACADIA Pharmaceuticals’ latest earnings call struck an upbeat tone as management highlighted record adjusted revenue above $1 billion and broad-based double-digit growth from both NUPLAZID and DAYBUE. While regulatory and policy headwinds, including European uncertainty and IRA impacts, weighed on margins, executives emphasized strong cash reserves and a rich pipeline as key drivers of sustained expansion.

Record Revenue Milestone and Growth Profile

ACADIA reported adjusted 2025 total revenues of $1.08 billion, up 14% year over year, marking the first time the company has surpassed the $1 billion mark. Fourth-quarter adjusted revenues rose 16% to $298 million, underscoring accelerating momentum across the neurology-focused portfolio.

NUPLAZID: Volume-Led Commercial Strength

NUPLAZID continued to anchor ACADIA’s franchise with adjusted Q4 net sales of $189 million, up 17% from the prior year, and $692 million for 2025, a 15% annual increase. Volume growth of 13% in the quarter and 9% for the year, along with an 18% jump in new prescriptions, points to expanding physician adoption rather than simple price gains.

NUPLAZID Outlook Toward Billion-Dollar Peak

For 2026, management guided NUPLAZID net sales to $760–$790 million, implying 10%–14% growth over 2025 and a gross-to-net discount of 22%–24%. The company reiterated its long-term trajectory toward roughly $1 billion in annual NUPLAZID sales by 2028, assuming continued volume gains and effective field execution.

DAYBUE Growth and STIX Launch

DAYBUE delivered Q4 net product sales of $110 million, up 13% year over year, and $391 million for 2025, a 12% increase, with quarterly volume up 12%. The December 2025 FDA approval of DAYBUE STIX, a powder formulation for oral solution, has seen early commercial interest, and management believes it can add more than 400 incremental patients over two to three years.

Expanding DAYBUE’s International Footprint

Outside the U.S., ACADIA is building DAYBUE’s base through named patient supply programs that extend access while formal approvals are pursued. The liquid formulation has now been cleared in three markets, including a recent approval in Israel, supporting gradual international contribution despite EU uncertainties.

Pipeline Depth and Upcoming Catalysts

Management spotlighted four unique molecules with combined peak sales potential estimated near $11 billion, led by remlifanserin, which is targeted at Alzheimer’s and Lewy body-related psychosis. A Phase II readout for remlifanserin is expected between August and October 2026, alongside a Phase III trofinetide trial in Japan and plans to start five additional Phase II/III studies by the end of 2027.

Balance Sheet Strength and Tax Benefit

ACADIA ended 2025 with $820 million in cash, providing ample funding for commercial launches and late-stage R&D. The company also recorded a one-time noncash income tax benefit of about $250 million by releasing a valuation allowance on deferred tax assets, improving reported earnings without altering cash levels.

Commercial Execution and Field Force Expansion

To support growth, ACADIA expanded its NUPLAZID customer-facing team by roughly 30%, boosting its prescriber target universe from around 7,000 to 11,000 by early 2026. For DAYBUE, community-based physicians are increasingly important, accounting for 76% of new prescriptions in Q4, while shipments reached a record 1,070 patients in the quarter.

EU Setback for DAYBUE Adds Regulatory Uncertainty

The company disclosed a negative trend vote from the European regulator’s committee following an oral explanation on trofinetide, and it now expects an unfavorable final opinion. ACADIA plans to request a reexamination, a process of roughly four months, and has excluded potential EU sales from 2026 guidance, though it notes Europe contributes less than 15% to its 2028 DAYBUE outlook.

IRA-Driven Accounting Adjustment and Cash Impact

CMS invoices tied to the Inflation Reduction Act showed higher Medicare volume than previously accrued, forcing a change in estimate that cut reported net sales by a one-time $20 million across applicable periods. The company paid $108 million over the first two years of IRA-related invoices, resulting in a net cash outflow of about $30 million in 2025 and highlighting tangible policy-driven pressure.

Rising SG&A and Gross-to-Net Headwinds

Selling, general and administrative expenses climbed to $156 million in Q4 from $130 million a year earlier, reflecting heavy investment in marketing and field expansion, with 2026 SG&A projected at $660–$700 million. NUPLAZID’s gross-to-net was 29.4% reported in Q4, 23.6% on an adjusted basis, and 25.9% for the year, pointing to sizable discounts and payer dynamics that weigh on realized pricing.

Pipeline and Execution Risks Remain Central

Management acknowledged that key catalysts such as the remlifanserin Phase II readout face typical clinical uncertainties, including placebo effects and trial design risk. Longer-term growth targets for both NUPLAZID and pipeline assets depend on smooth Phase II/III execution and competition management, with rival therapies and broader industry operational issues cited as watch points.

Guidance and Long-Term Targets Underpin Growth Story

ACADIA guided 2026 adjusted total revenues to $1.22–$1.28 billion, driven by NUPLAZID net sales of $760–$790 million and DAYBUE global sales of $460–$490 million, both assuming gross-to-net in the low-20% range. Management reiterated 2028 goals of about $1 billion for NUPLAZID and $700 million for DAYBUE, implying a compound annual growth rate near 16% and operating margins trending from mid-teens toward the low-20s under typical R&D attrition.

ACADIA’s earnings call painted the picture of a company in the midst of a strong commercial ramp, underpinned by growing neurology brands and a sizable late-stage pipeline. While regulatory setbacks in Europe, IRA headwinds, and elevated operating spend temper near-term profitability, investors heard a confident message that top-line growth, ample cash, and upcoming trial readouts can sustain the story over the next several years.